SUMO1 Antikörper (full length) (FITC)

Produktnummer ABIN2452136

Es sind 4+ Publikationen für dieses Produkt verfügbar. Der Ratte Monoklonal anti-SUMO1 Antikörper wird verwendet zum Nachweis von SUMO1 in Proben von Human. Er wurde validiert für WB, IF und IHC (p).

Kurzübersicht für SUMO1 Antikörper (full length) (FITC) (ABIN2452136)

Target: SUMO1 (Small Ubiquitin Related Modifier Protein 1 (SUMO1))

Reaktivität: Human

Wirt: Ratte

Klonalität: Monoklonal

Konjugat: Dieser SUMO1 Antikörper ist konjugiert mit FITC

Applikation: Western Blotting (WB), Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Klon: 4D12

Produktdetails anti-SUMO1 Antikörper (FITC)

Bindungsspezifität: full length

Spezifität: Specific to human, simian, mouse and rat SUMO1.

Kreuzreaktivität (Details): Not tested for other species

Aufreinigung: The antibody was produced in serum-free medium and purified by proprietary chromatography procedures under mild conditions and conjugated with FITC.

Sterilität: Sterile filtered

Immunogen: Recombinant GST-fused human SUMO-1 (full length)

Isotyp: IgG2a kappa

Anwendungsinformationen

Applikationshinweise: 1. Immunofluorescence staining: 1/100 dilution
2. Immunohistochemistry,frozen section: 1/100 dilution

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 mg/mL

Buffer: PBS (x1), 50 % glycerol. Azide and carrier free.

Konservierungsmittel: Azide free

Lagerung: -20 °C

Referenzen für anti-SUMO1 Antikörper (FITC) (ABIN2452136)

Ulrich: "The fast-growing business of SUMO chains." in: Molecular cell, Vol. 32, Issue 3, pp. 301-5, (2008) (PubMed).

Saitoh, Uchimura, Tachibana, Sugahara, Saitoh, Nakao: "In situ SUMOylation analysis reveals a modulatory role of RanBP2 in the nuclear rim and PML bodies." in: Experimental cell research, Vol. 312, Issue 8, pp. 1418-30, (2006) (PubMed).

Cheng, Bawa, Lee, Gong, Yeh: "Role of desumoylation in the development of prostate cancer." in: Neoplasia (New York, N.Y.), Vol. 8, Issue 8, pp. 667-76, (2006) (PubMed).

Uchimura, Ichimura, Uwada, Tachibana, Sugahara, Nakao, Saitoh: "Involvement of SUMO modification in MBD1- and MCAF1-mediated heterochromatin formation." in: The Journal of biological chemistry, Vol. 281, Issue 32, pp. 23180-90, (2006) (PubMed).

Details zu SUMO1

Target: SUMO1 (Small Ubiquitin Related Modifier Protein 1 (SUMO1))

Andere Bezeichnung: SUMO1

Hintergrund: SUMO (Small Ubiquitin-like Modifier) proteins are a family of small proteins that are covalently attached to and detached from other proteins in cells to modify their function. Unlike ubiquitination, which targets proteins for degradation, SUMO modification plays a critical role in a number of cellular functions including nucleocytoplasmic transport, gene expression, cell cycle and formation of subnuclear structures such as promyelocytic leukemia (PML) bodies. There are three confirmed SUMO isoforms in human, SUMO1, SUMO2 and SUMO3. SUMO2 /3 show a high degree of similarity to each other and are distinct from SUMO-1. Individual SUMO family members are all targeted to different proteins with diverse biological functions. SUMO-1 is conjugated to RanGAP, PML, p53 and IkappaB-alpha to regulate nuclear trafficking, formation of subnuclear structures, regulation of transcriptional activity and protein stability. SUMO1 is encoded as a 101 aa protein and first Met and C-terminal 4 aa are removed from the preprotein.

UniProt: P63165

Pathways: M Phase, Positive Regulation of Endopeptidase Activity, Protein targeting to Nucleus, Ubiquitin Proteasome Pathway